Sign in

    Adi on

    Research Analyst at Evercore ISI

    Adi Jayaraman is Senior Managing Director in Evercore’s Technology group, specializing in M&A and capital markets transactions for fintech and information services companies. With nearly twenty years of industry experience, Jayaraman has advised on deals representing more than $100 billion in announced value, covering firms in high-growth fintech, digital finance, market structure, payments, and financial data. He began his career at Morgan Stanley, then served in lead roles at J.P. Morgan and Citi before joining Evercore; his credentials include an MBA from the Wharton School, an M.S. in computer science from Baruch College, and a B.A. in economics from the University of Delhi. Jayaraman's expertise and track record have established him as a leader in global technology advisory, though specific investment performance rankings or securities licenses are not publicly listed.

    Adi on's questions to Moderna (MRNA) leadership

    Adi on's questions to Moderna (MRNA) leadership • Q2 2025

    Question

    Adi, on for Cory Kasimov, asked for the rationale behind starting a first-line metastatic melanoma trial for intismarin and about regulatory interactions regarding the path forward for the checkpoint program.

    Answer

    President Stephen Hoge stated that strong data from the adjuvant melanoma study and manufacturing advancements prompted the expansion into metastatic disease. For the checkpoint program, he confirmed early-stage regulatory discussions are underway, but the 2028 filing target primarily reflects internal prioritization and conviction in the program's potential.

    Ask Fintool Equity Research AI